17.74

3.26% 0.56

After Hours: 17.74

Neogenomics Inc (NEO)

Overview News Price History Option Chain Financials Why NEO Down? Discussions Forecast Stock Split

Neogenomics Inc stock is traded at $17.74, with a volume of 423.98K. It is up +3.26% in the last 24 hours and up +35.73% over the past month. NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

Previous Close:

$17.18

Open:

$17.31

24h Volume:

423.98K

Relative Volume:

0.63

Market Cap:

$2.24B

Revenue:

$628.25M

Net Income/Loss:

$-78.55M

P/E Ratio:

-23.04

EPS:

-0.77

Net Cash Flow:

$-29.73M

1W Performance:

+15.49%

1M Performance:

+35.73%

6M Performance:

+24.58%

1Y Performance:

-6.78%

1-Day Range:

$17.31

$17.78

1-Week Range:

$14.99

$17.78

52-Week Range:

$12.77

$21.22

Neogenomics Inc Stock (NEO) Company Profile

Name

Neogenomics Inc

Sector

Healthcare (1200)

Industry

Diagnostics & Research (57)

Phone

(239) 768-0600

Address

9490 NEOGENOMICS WAY, FORT MYERS, FL

Employee

2,100

Twitter

@NeoGenomics

Next Earnings Date

2024-11-05

Latest SEC Filings

NEO's Discussions on Twitter

Compare NEO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NEO Neogenomics Inc	17.74	2.24B	628.25M	-78.55M	-29.73M	-0.77
TMO Thermo Fisher Scientific Inc	521.66	199.82B	42.37B	6.14B	7.78B	15.26
DHR Danaher Corp	238.83	173.66B	23.74B	3.89B	4.98B	7.93
A Agilent Technologies Inc	138.14	38.64B	6.51B	1.29B	1.37B	3.82
IQV Iqvia Holdings Inc	201.43	36.52B	15.32B	1.41B	1.96B	5.95
IDXX Idexx Laboratories Inc	421.76	34.55B	3.84B	866.24M	792.60M	9.80

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-01-24	Resumed	Craig Hallum	Buy
Dec-29-23	Reiterated	BTIG Research	Buy
Aug-21-23	Upgrade	Stephens	Equal-Weight → Overweight
May-16-23	Downgrade	Raymond James	Outperform → Mkt Perform
May-09-23	Upgrade	BTIG Research	Neutral → Buy
Feb-24-23	Upgrade	The Benchmark Company	Hold → Buy
Feb-01-23	Upgrade	Needham	Hold → Buy
Aug-26-22	Downgrade	The Benchmark Company	Buy → Hold
Aug-22-22	Downgrade	Needham	Buy → Hold
Jun-03-22	Initiated	Piper Sandler	Overweight
Mar-29-22	Downgrade	BofA Securities	Buy → Neutral
Mar-29-22	Downgrade	Stephens	Overweight → Equal-Weight
Jan-18-22	Resumed	Stephens	Overweight
Dec-16-21	Initiated	Cowen	Outperform
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-14-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-03-21	Initiated	Goldman	Buy
Feb-25-21	Resumed	Needham	Buy
Feb-25-21	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-28-21	Initiated	Truist	Buy
Dec-11-20	Resumed	BTIG Research	Buy
Oct-28-20	Reiterated	Needham	Buy
Sep-09-20	Initiated	Morgan Stanley	Overweight
Aug-28-20	Initiated	Guggenheim	Buy
Jul-29-20	Reiterated	Needham	Buy
Jun-25-20	Initiated	BofA/Merrill	Buy
Apr-21-20	Resumed	Stephens	Overweight
Mar-02-20	Resumed	Craig Hallum	Buy
Feb-28-20	Upgrade	First Analysis Sec	Outperform → Strong Buy
Jan-23-20	Downgrade	First Analysis Sec	Strong Buy → Outperform
Oct-30-19	Reiterated	Needham	Buy
May-01-19	Reiterated	Needham	Buy
Mar-29-19	Reiterated	Needham	Buy
Jan-03-19	Initiated	Needham	Buy
Oct-24-18	Upgrade	First Analysis Sec	Outperform → Strong Buy
Aug-21-18	Initiated	Leerink Partners	Outperform
May-02-18	Downgrade	First Analysis Sec	Overweight → Equal-Weight
Sep-11-17	Downgrade	BTIG Research	Buy → Neutral
Aug-24-17	Initiated	Gabelli & Co	Buy
Dec-15-16	Initiated	Cantor Fitzgerald	Overweight

View All

Neogenomics Inc Stock (NEO) Latest News

Nov 27, 2024

Loomis Sayles & Co. L P Invests $17.81 Million in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat

Nov 27, 2024

Nov 23, 2024

NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable - Simply Wall St

Nov 23, 2024

NeoGenomics, Inc. (NASDAQ:NEO) Stock Holdings Raised by Jennison Associates LLC - MarketBeat

Nov 23, 2024

Nov 22, 2024